Humana Inc

Humana’s Q1 earnings beat expectations, driven by cost‑control and new telehealth plans, positioning it as a top‑performing, defensively‑oriented insurer in the current market.

Humm Group’s board stays unchanged, while a $22 M legal settlement with SMBC clears a major liability, giving investors confidence and a modest share‑price lift.

Humm Group’s board overhaul, litigation settlement and new securities policy boost governance, reduce risk and lower capital costs, positioning the company for growth in digital health and value‑based reimbursement.

Humana partners with Cost Plus Drugs’ SwiftyRx to offer real‑time e‑Rx, mail‑order delivery and enhanced safety for members, boosting efficiency and adherence.

Medicare Advantage 2027 rates rise 1.3%, boosting insurer margins and easing premium pressure—UnitedHealth, Humana see gains while quality‑based incentives grow.

Medicare Advantage rate hike boosts U.S. insurers’ profits – Humana gains $13 bn, higher margins and tech investments ahead of 2027.

Humana insider trades, a 57% five‑year decline, and mid‑cap dynamics—insight into executive confidence, option impact, and market risks.

Humana’s March 2026 strategy blends board realignment, CGM adoption and AI to boost Medicare Advantage profits, cut costs, and win CMS bonus payments.

Humana’s recent stock rebound, stable P/E, and focus on coordinated care and provider stability in Medicare Advantage signal resilience and growth potential for investors, clinicians, and patients alike.

Humana’s Q4 beats expectations but 2026 guidance falls short, sparking concerns. Learn how the company’s primary‑care expansion, MaxHealth deal, and margin pressures shape its future.